Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15

Excerpt A Phase 3 clinical study called Vaccine Against Lyme for Outdoor Recreationists (VALOR) (NCT05477524) has been launched by Pfizer Inc. and Valneva SE to examine the efficacy, safety, and immunogenicity of their investigational Lyme disease vaccine candidate, VLA15. Article Summary Approximately 6,000 participants 5 years of age and older are expected to enrol in […]

Bharat Biotech declares that the intranasal Covid vaccination booster has “proved to be safe” and ends intranasal Covid vaccine booster trials

Excerpt Bharat Biotech has submitted data from Phase 3 clinical trials of BBV154, its intranasal Covid vaccine candidate, to the drug regulator. It has sought approval both as a primary two-dose vaccine, and a heterologous booster shot. Article Summary A heterologous booster suggests that the vaccine’s third or subsequent doses are distinct from the first […]

Homegrown Vaccines on the way for Australia

Excerpt With the completion of all agreements for the 10-year cooperation, the Australian Government, Moderna, and the Victorian Government marked a significant advancement in the onshore production of life-saving mRNA vaccines. Article Summary With the completion of all agreements for the 10-year cooperation, the Australian Government, Moderna, and the Victorian Government marked a significant advancement […]

BioNTech Starts Construction of First mRNA Vaccine Manufacturing Facility in Africa 

Excerpt The first container modules are expected to be delivered by the end of 2022 from Kigali, Rwanda, the site of BioNTech’s first African modular mRNA manufacturing factory. The facility will come with two BioNTainers initially, and it is anticipated that by 2024, there will be roughly 100 employees working there.  BioNTech’s malaria vaccine candidates […]

Aerosol-based TB vaccine begins human trials

The University of Oxford has begun recruiting for a Phase I trial with a tuberculosis vaccine in human volunteers at Oxford to develop a new way to test the efficacy of future TB vaccines Article Summary: Because humans cannot be safely exposed to the TB-causing germs, it has not yet been able to perform a […]

Sanofi-GSK first to report a successful efficacy study against Omicron with COVID-19 Beta-containing vaccine

Excerpt Primary vaccination with Beta-containing vaccine candidate delivers 64.7% efficacy against symptomatic infection in adults, and 75.1% efficacy in participants previously infected with COVID-19Article Summary Sequencing analysis has shown 72 percent efficacy against Omicron in adults overall and 93.2 percent in seropositives. Favorable safety and tolerability profile First-ever efficacy findings in an Omicron setting indicate […]

NIH launches clinical trial of mRNA Nipah virus vaccine

Excerpt An early-stage clinical trial evaluating an investigational vaccine to prevent Nipah virus infection has been started by the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health Article Summary An early-stage clinical trial evaluating an investigational vaccine to stave off Nipah virus infection has been started by […]

Pfizer and Valneva enter into an equity subscription agreement and update the terms of the collaboration agreement for Lyme disease vaccine candidate VLA15.

Excerpt Pfizer will invest €90.5 million in Valneva Planned Phase 3 study confirmed to initiate in Q3 2022   Article Summary Valneva announced that they have entered into an Equity Subscription Agreement and have updated the terms of their Collaboration and License Agreement for Lyme disease vaccine candidate VLA15. As part of the Equity Subscription […]

Covid-19 vaccine

World Bank Support for Country Access to COVID-19 Vaccines

Excerpt The World Bank has approved $9.5 billion in operations to assist vaccination rollout in 77 countries as of June 15, 2022. Article Summary The World Bank Group is collaborating with partners on the world’s largest vaccine programme to combat the COVID-19 pandemic. The World Bank’s Board of Executive Directors adopted a $6 billion Global […]

Pneumococcal vaccines

GSK to acquire clinical-stage biopharmaceutical company Affinivax, Inc.

Excerpt GSK will pay $2.1 billion up front and up to $1.2 billion in development milestone payments. The proposed acquisition will give the company access to a next-generation 24-valent pneumococcal vaccine candidate in phase II development as well as MAPSTM technology, which is extremely innovative. Encourages the development of a diverse portfolio of novel vaccines […]

Madiba pharmaceutical

The European Investment Bank (EIB) has provided €75 million to the Institut Pasteur de Dakar for the construction of a new vaccine manufacturing facility.

Excerpt Large-scale funding for the Institut Pasteur de Dakar’s new vaccine manufacturing facility, a leader in the area in Africa. The facility, which would produce up to 300 million doses per year against COVID-19 and other endemic diseases, is projected to considerably reduce Africa’s reliance on imported vaccines and support equal access to medicines. This […]

COVID-19 and the Cold Chain: Lessons from the front lines of the vaccine rollout

Article Summary: Ensuring the safe handling, delivery and administration of more than a half-billion COVID-19 vaccines in the United States in less than two years was an unprecedented logistical feat. But distributing the two approved mRNA vaccines from Pfizer-BioNTech and Moderna has been a particular challenge, given the vaccines’ extreme temperature control requirements, according to […]